198 related articles for article (PubMed ID: 16103104)
1. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
Honeychurch J; Glennie MJ; Illidge TM
Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
[TBL] [Abstract][Full Text] [Related]
2. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
French RR; Chan HT; Tutt AL; Glennie MJ
Nat Med; 1999 May; 5(5):548-53. PubMed ID: 10229232
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.
Tutt AL; French RR; Illidge TM; Honeychurch J; McBride HM; Penfold CA; Fearon DT; Parkhouse RM; Klaus GG; Glennie MJ
J Immunol; 1998 Sep; 161(6):3176-85. PubMed ID: 9743386
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
5. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model.
Fuentes D; Avellanet J; Garcia A; Iglesias N; Gabri MR; Alonso DF; Vazquez AM; Perez R; Montero E
Breast Cancer Res Treat; 2010 Apr; 120(2):379-89. PubMed ID: 19377876
[TBL] [Abstract][Full Text] [Related]
6. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
7. CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells.
Bergstrom RT; Silverman DA; Chambers K; Kim JA
Otolaryngol Head Neck Surg; 2004 Jan; 130(1):94-103. PubMed ID: 14726917
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
Song W; Levy R
Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
10. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
11. Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells.
Marches R; Racila E; Tucker TF; Picker L; Mongini P; Hsueh R; Vitetta ES; Scheuermann RH; Uhr JW
Ther Immunol; 1995 Jun; 2(3):125-36. PubMed ID: 8885131
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model].
Zhou H; Xi H; Ma QR; Chen C; Zhang F; Zhang XG; Gu ZJ
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):181-5. PubMed ID: 17649632
[TBL] [Abstract][Full Text] [Related]
13. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
14. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
15. CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.
Kwekkeboom J; De Boer M; Tager JM; De Groot C
Immunology; 1993 Jul; 79(3):439-44. PubMed ID: 7691726
[TBL] [Abstract][Full Text] [Related]
16. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
17. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
18. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
19. Functional and in situ evidence for nitric oxide production driven by CD40-CD40L interactions in graft-versus-leukemia reactivity.
Müerköster S; Laman JD; Rocha M; Umansky V; Schirrmacher V
Clin Cancer Res; 2000 May; 6(5):1988-96. PubMed ID: 10815924
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody reactive with a 40-kDa molecule on fetal thymocytes and tumor cells blocks proliferation and stimulates aggregation and apoptosis.
Fernandes DM; Baird AM; Berg LJ; Rock KL
J Immunol; 1999 Aug; 163(3):1306-14. PubMed ID: 10415028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
